Guanosine

Guanosine

SCHEMBL4879720

Nc1ccn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1.Nc1nc2c(ncn2[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY2 P41231 4/20 0.59
P2RY4 P51582 4/20 0.59
P2RY6 Q15077 3/20 0.59
LMNA P02545 1/20 0.56
THRB P10828 1/20 0.56
MTOR P42345 1/20 0.56
MDM2 Q00987 1/20 0.56
NCOA1 Q15788 1/20 0.56
NCOA3 Q9Y6Q9 1/20 0.56
HPGD P15428 1/20 0.55
GSK3A P49840 2/20 0.53
RPS6KA3 P51812 2/20 0.53
MAPK14 Q16539 2/20 0.53
PNP P00491 1/20 0.52
HINT1 P49773 2/20 0.51
NT5E P21589 1/20 0.51
DNMT1 P26358 4/20 0.51
FPR2 P25090 2/20 0.51
DNMT3B Q9UBC3 2/20 0.51
POLB P06746 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Deoxyguanosine SCHEMBL2498296 0.93 POLB (0.57) P2RY2P2RY4P2RY6LMNATHRB
Guanosine SCHEMBL536141 0.91 LMNA (0.69) LMNATHRBMTORMDM2NCOA1
Guanosine SCHEMBL8524537 0.91 HPGD (0.63) P2RY2P2RY4P2RY6LMNAHPGD
Guanosine SCHEMBL5027190 0.91 HPGD (0.63) P2RY2P2RY4P2RY6LMNAHPGD
Guanosine SCHEMBL10528215 0.88 F2 (0.64) P2RY2P2RY4P2RY6LMNATHRB
Guanosine SCHEMBL1983917 0.88 LMNA (0.64) P2RY2P2RY4P2RY6LMNATHRB
Guanosine SCHEMBL11023852 0.86 DTYMK (0.61) P2RY2P2RY4P2RY6DNMT1FPR2
Deoxyguanosine SCHEMBL20445785 0.85 POLB (0.67) P2RY2P2RY4P2RY6LMNAPNP
Guanosine SCHEMBL27546322 0.85 ADORA3 (0.63) LMNATHRBMTORMDM2NCOA1
Guanosine SCHEMBL4874332 0.85 DNMT1 (0.63) P2RY2P2RY4P2RY6HPGDDNMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080145372-A1 Bioreductively-Activated Prodrugs ANGIOGENE, PHARMACEUTICALS LIMITED (GB) 2008-06-19 US disclosed
EP-1799698-A1 BIOREDUCTIVELY-ACTIVATED PRODRUGS Angiogene Pharmaceuticals Limited (GB) 2007-06-27 EP disclosed
WO-2006032921-A1 BIOREDUCTIVELY-ACTIVATED PRODRUGS ANGIOGENE PHARMACEUTICALS LIMITED (GB) 2006-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080145372-A1 Bioreductively-Activated Prodrugs NME2, PNP, NUDT1 P2RY2 150/4885P2RY4 610/4885P2RY6 215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.